There is a section on securing best value for patients from drugs and devices, which notes that NHS England intends to roll out use of systems such as Blueteq to support usage decisions for excluded drugs and devices on a wider basis during 2015/16. All acute trusts with a current contract spend on excluded drugs and devices above £15m will have a CQUIN to support this change